Investor Presentation First Nine Months of 2022
15
Investor presentation First nine months of 2022
Financial results - First nine months of 2022
Novo NordiskⓇ
In DKK million
Sales
Gross profit
Gross margin
First nine
months of 2022
First nine
Change
Change
128,862
months of 2021
102,467
(reported)
(CER)
26%
16%
Sales and distribution costs
Percentage of sales
Research and development costs
108,676
84.3%
(32,474)
25.2%
(15,962)
85,050
28%
17%
83.0%
(25,376)
28%
19%
24.8%
(12,140)
31%
26%
Percentage of sales
12.4%
11.8%
Administration costs
(3,119)
(2,860)
9%
5%
Percentage of sales
2.4%
2.8%
Other operating income and expenses
601
336
79%
58%
Operating profit
57,722
45,010
28%
14%
Operating margin
44.8%
43.9%
Financial items (net)
Profit before income tax
Income taxes
(4,976)
52,746
(10,813)
957
45,967
15%
(9,102)
19%
Effective tax rate
20.5%
19.8%
Net profit
41,933
36,865
14%
Diluted earnings per share (DKK)
18.42
15.98
15%
CER: Constant exchange ratesView entire presentation